Additional information
| Quantity | 28 TABS, 84 TABS |
|---|
Veoza 45mg Tablets contain fezolinetant, a non-hormonal prescription medicine used to treat moderate to severe hot flushes and night sweats associated with menopause, also known as vasomotor symptoms (VMS).
Unlike hormone replacement therapy (HRT), Veoza does not contain oestrogen or progesterone. It works by blocking neurokinin 3 (NK3) receptors involved in the brain’s temperature regulation, helping reduce the frequency and severity of menopause-related hot flushes.
Veoza is taken once daily and is available in two supply quantities:
28 tablets
84 tablets
£99.00 – £237.00Price range: £99.00 through £237.00

Safe & compliant prescribing

UK-Registered Pharmacy

Quick, hassle-free online consultation

Your data is 100% protected

Next-day UK delivery available

NHS Providing Service since 2020
| Quantity | 28 TABS, 84 TABS |
|---|
Veoza 45mg – Non-Hormonal Relief from Menopause Hot Flushes and Night Sweats
Veoza 45mg Film-Coated Tablets are a prescription-only, non-hormonal medicine developed to treat moderate to severe vasomotor symptoms associated with menopause.
During menopause, changes in oestrogen levels affect the body’s temperature regulation system. This can lead to sudden sensations of intense heat, flushing, sweating and night sweats, which may interrupt sleep and everyday activities.
Veoza contains fezolinetant, a neurokinin 3 (NK3) receptor antagonist. Rather than replacing declining hormone levels, it acts on specific signalling pathways in the brain involved in controlling body temperature.
By blocking NK3 receptor activity, Veoza helps reduce the frequency and severity of hot flushes and night sweats.
Veoza may provide a treatment option for women who prefer a non-hormonal approach or for whom hormone replacement therapy is unsuitable. However, it is not appropriate for everyone, and prescribing requires an assessment of medical history, liver health and potential medicine interactions.
How Does Veoza Work?
The hypothalamus is the part of the brain responsible for regulating body temperature.
During menopause, declining oestrogen levels can affect nerve cells involved in temperature control. These include KNDy neurons, which use neurokinin B signalling.
Increased activity in this pathway contributes to the narrowing of the body’s temperature regulation range, triggering hot flushes and sweating.
Veoza blocks NK3 receptors, reducing the effect of neurokinin B signalling on the body’s temperature regulation system.
This helps control menopause-related hot flushes and night sweats without directly replacing oestrogen.
What Symptoms Does Veoza Treat?
Veoza is specifically licensed to treat:
Moderate to severe hot flushes associated with menopause.
Moderate to severe night sweats associated with menopause.
By reducing night sweats, it may also improve sleep that is disrupted by these symptoms.
However, Veoza is not licensed to treat every menopause symptom. It is not a treatment for vaginal dryness, osteoporosis or other conditions caused by oestrogen deficiency.
Veoza Compared with Hormone Replacement Therapy
| Feature | Veoza | Traditional HRT |
|---|---|---|
| Treatment type | Non-hormonal | Hormonal |
| Main action | Blocks NK3 receptors | Replaces or supplements hormones |
| Contains oestrogen | No | Often |
| Contains progesterone | No | Depends on formulation |
| Treats hot flushes | Yes | Yes |
| Treats night sweats | Yes | Yes |
| Treats vaginal dryness | Not specifically | Some HRT formulations can |
| Requires liver monitoring | Yes, specific mandatory schedule | Depends on clinical circumstances |
| Administration | Once-daily tablet | Tablets, patches, gels or sprays |
Veoza is not automatically safer than HRT. Each treatment has different benefits, risks, contraindications and monitoring requirements.
Key Benefits
Non-hormonal treatment for menopause-related hot flushes.
Helps reduce the frequency and severity of night sweats.
Contains fezolinetant 45mg per tablet.
Does not contain oestrogen or progesterone.
Works through NK3 receptors involved in temperature regulation.
Convenient once-daily oral administration.
May improve sleep disrupted by night sweats.
Offers an alternative treatment approach for selected women who cannot or prefer not to use HRT.
Available in 28-tablet and 84-tablet supply quantities.
Does not require additional progesterone for womb-lining protection because it is not an oestrogen treatment.
Product Details
| Detail | Information |
|---|---|
| Product Name | Veoza 45mg Tablets |
| Active Ingredient | Fezolinetant |
| Strength | 45mg per tablet |
| Brand | Veoza |
| Manufacturer | Astellas Pharma |
| Medicine Type | Non-hormonal menopause treatment |
| Drug Class | Neurokinin 3 receptor antagonist |
| Form | Film-coated oral tablets |
| Pack Options | 28 or 84 tablets |
| Main Use | Moderate to severe menopausal vasomotor symptoms |
| Recommended Dose | One 45mg tablet daily |
| Administration | Oral |
| Prescription Required | Yes |
| Liver Function Monitoring | Required |
Veoza must be taken exactly as prescribed by your doctor or pharmacist.
Recommended Dosage
The recommended dose is one Veoza 45mg tablet once daily.
How to Take Veoza
Take one tablet every day at approximately the same time.
Swallow the tablet whole with water.
Veoza can be taken with or without food.
Do not break, crush or chew the tablet.
Continue treatment according to your prescribed schedule.
Attend all required liver function blood tests.
Do not take more than one tablet daily to make up for a missed dose.
What If You Miss a Dose?
If you forget to take Veoza, take the missed tablet as soon as possible unless there are fewer than 12 hours before your next scheduled dose.
If fewer than 12 hours remain, skip the missed dose and continue your usual schedule the following day.
Do not take a double dose.
How Long Does Each Pack Last?
| Pack quantity | Daily dose | Duration |
|---|---|---|
| 28 tablets | One tablet | 28 days |
| 84 tablets | One tablet | 84 days |
Liver Function Monitoring Requirements
Because Veoza has been associated with serious drug-induced liver injury, liver function monitoring is essential.
| Monitoring stage | Requirement |
|---|---|
| Before treatment | Liver function blood tests |
| First month | Repeat liver function tests |
| Second month | Repeat liver function tests |
| Third month | Repeat liver function tests |
| After three months | Further tests based on clinical judgement |
| If liver symptoms develop | Immediate medical assessment and liver function testing |
Treatment must not be started if ALT or AST levels are at least twice the upper limit of normal, or if total bilirubin is significantly elevated as specified in the prescribing information.
Your prescriber will assess your results and determine whether treatment can be started or continued.
Active Ingredient
Each film-coated tablet contains:
Fezolinetant 45mg.
Other Ingredients
Tablet core:
Mannitol (E421).
Hydroxypropyl cellulose (E463).
Low-substituted hydroxypropyl cellulose (E463a).
Microcrystalline cellulose (E460).
Magnesium stearate (E470b).
Film coating:
Hypromellose (E464).
Talc (E553b).
Macrogol (E1521).
Titanium dioxide (E171).
Red iron oxide (E172).
These ingredients are listed in the UK Summary of Product Characteristics.
Like all medicines, Veoza can cause side effects, although not everyone experiences them.
Common Side Effects
The following have been reported in clinical studies:
Diarrhoea.
Difficulty sleeping (insomnia).
Abdominal pain.
Increased liver enzymes (ALT or AST) detected through blood tests.
Diarrhoea and insomnia were among the most frequently reported adverse reactions.
Serious Side Effects – Liver Injury
Veoza has been associated with serious cases of drug-induced liver injury, including cases reported after the medicine became available.
Stop taking Veoza and seek immediate medical advice if you develop:
Yellowing of the skin or whites of the eyes (jaundice).
Dark urine.
Pale-coloured stools.
Unusual or persistent tiredness.
Severe or persistent itching.
Nausea or vomiting.
Loss of appetite.
Abdominal pain.
These symptoms may indicate liver injury and require urgent assessment.
Some patients develop abnormal liver function tests without noticeable symptoms, which is why regular blood tests are required.
Do Not Take Veoza If You:
Are allergic to fezolinetant or any other ingredient.
Are taking medicines that moderately or strongly inhibit the CYP1A2 enzyme.
Are pregnant or think you may be pregnant.
Speak to Your Doctor Before Taking Veoza If You:
Have liver disease or a history of liver problems.
Have abnormal liver function blood test results.
Have severe kidney problems.
Have a history of breast cancer or another oestrogen-dependent cancer.
Are currently receiving treatment for an oestrogen-dependent cancer.
Have a history of seizures or convulsive disorders.
Are taking hormone replacement therapy containing oestrogen.
Take other prescription medicines, over-the-counter products or herbal supplements.
Important Medicine Interactions
Veoza must not be used with moderate or strong CYP1A2 inhibitors because they can substantially increase fezolinetant exposure.
Examples include:
Fluvoxamine.
Mexiletine.
Enoxacin.
Certain contraceptives containing ethinylestradiol.
Your prescriber or pharmacist must review your complete medication list before treatment.
Other Important Precautions
Liver disease: Veoza should be avoided in patients with known liver disease or a higher risk of liver injury. It is not recommended for moderate or severe chronic hepatic impairment.
Kidney disease: Veoza is not recommended for severe kidney impairment or end-stage renal disease.
Breast cancer: Safety has not been established in women undergoing treatment for breast cancer or other oestrogen-dependent malignancies. Veoza is not recommended during such treatment.
HRT: Using Veoza alongside systemic oestrogen HRT has not been adequately studied and is not recommended.
Pregnancy: Veoza must not be used during pregnancy. Women who could become pregnant should discuss effective contraception with their prescriber.
Breastfeeding: Veoza is not indicated during breastfeeding.
Older patients: There is insufficient evidence to establish a dosing recommendation for women starting Veoza after 65 years of age.
Veoza does not require any special storage conditions.
Keep tablets in their original packaging.
Keep out of the sight and reach of children.
Do not use after the expiry date printed on the packaging.
Do not use tablets if the blister packaging is damaged.
Return unused or expired medicine to a pharmacy for safe disposal.





This website sells age-restricted products. Please confirm you are 18 years of age or older to continue.
Sorry, you must be 18 years or older to access this website.
Leave Site
Reviews
There are no reviews yet.